Advances in the Imaging of Pituitary Tumors.
James MacFarlane, Waiel A Bashari, Russell Senanayake...
https://pubmed.ncbi.nlm.nih.gov/32741476Actively Recruiting
Phase Not Applicable
Age: 18Years - 100Years
All Genders
ID06584123
Exploring 18F-fluoro-ethyl-tyrosine (18F-FET) PET for Molecular Imaging in Patients With Pituitary Adenomas
Led by University of Cambridge · Updated on 2026-01-06
20
Participants Needed
1
Research Sites
17 weeks
Total Duration
On this page
Sponsors
U
University of Cambridge
Lead Sponsor
C
Cambridge University Hospitals NHS Foundation Trust
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are evaluating whether 18F-fluoro-ethyl-tyrosine PET (FET-PET) scans provide similar results to 11C-methionine PET (Met-PET) scans for locating pituitary tumors. This pilot study focuses on patients with pituitary adenomas, including those newly diagnosed or with residual or recurrent tumors after previous treatments. The study aims to determine if FET-PET could be a useful imaging method for these patients. In this study, up to 20 patients who have already undergone Met-PET scans as part of their routine care will receive a FET-PET scan. Both quantitative and qualitative analyses will compare the results of the two types of PET scans to assess their similarity in detecting pituitary adenomas. All participants will have an 18F-FET-PET scan during the study. Participants will be assessed using PET scans to measure the maximum standardized uptake values (SUVmax) over their pituitary tumors and surrounding areas. The study includes evaluating uptake in normal pituitary glands and nearby structures. Safety and tolerability will be monitored throughout the process. The total participation duration involves a single-day imaging assessment with follow-up as needed.
CONDITIONS
Brief Title
Molecular Pituitary Imaging Using 18F-FET PET
Who Can Participate
Age: 18Years - 100Years
All Genders
Eligibility Criteria
You may qualify if you...
- Participant is willing and able to give informed consent for participation in the study
- Male or female, age 18 or above
- Presence of pituitary adenoma suspected on the basis of clinical/biochemical and/or radiological findings
- Previous 11C-Met-PET/CT
You will not qualify if you...
- Inability to give informed consent
- Pregnancy or suspected pregnancy
- Inability to lie supine for 30-60 minutes
- Patient body habitus above scanner dimensions
- Known allergy to intravenous radiographic contrast agents
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
1
2
3
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Diagnostic Evaluation
Duration - 1 day
Participants undergo an 18F-fluoroethyltyrosine (FET) PET scan to assess pituitary adenomas.
1 visit (in-person)
Long-term Monitoring
Duration - Up to several months following the scan
Participants are observed after the diagnostic evaluation for any follow-up assessments or outcomes.
Additional visits may occur depending on clinical need
Trial Site Locations
Total: 1 location
1
Cambridge University Hospitals
Cambridge, Cambridgeshire, United Kingdom, CB2 0QQ
Actively Recruiting
Loading map...
Research Team
J
James MacFarlane
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Published Research Related To This Trial
Successful treatment of residual pituitary adenoma in persistent acromegaly following localisation by 11C-methionine PET co-registered with MRI.
Olympia Koulouri, Narayanan Kandasamy, Andrew C Hoole...
https://pubmed.ncbi.nlm.nih.gov/27562400A role for 11C-methionine PET imaging in ACTH-dependent Cushing's syndrome.
Olympia Koulouri, Andrea Steuwe, Daniel Gillett...
https://pubmed.ncbi.nlm.nih.gov/26245763Localisation of an occult thyrotropinoma with 11C-methionine PET-CT before and after somatostatin analogue therapy.
Olympia Koulouri, Andrew C Hoole, Patrick English...
https://pubmed.ncbi.nlm.nih.gov/27777050PET-guided repeat transsphenoidal surgery for previously deemed unresectable lateral disease in acromegaly.
Waiel A Bashari, Russell Senanayake, Olympia Koulouri...
https://pubmed.ncbi.nlm.nih.gov/32480379An interindividual comparison of O-(2-[18F]fluoroethyl)-L-tyrosine (FET)- and L-[methyl-11C]methionine (MET)-PET in patients with brain gliomas and metastases.
Anca-Ligia Grosu, Sabrina T Astner, Eva Riedel...
https://pubmed.ncbi.nlm.nih.gov/21570201Pituitary incidentaloma found on O-(2-18F-fluoroethyl)-l-tyrosine PET.
Geoffrey M Currie, Marko Trifunovic, Hosen Kiat...
https://pubmed.ncbi.nlm.nih.gov/24948822Tyrosine positron emission tomography and protein synthesis rate in pituitary adenoma: different effects of surgery and radiation therapy.
Alfons C M van den Bergh, Jan Pruim, Thera P Links...
https://pubmed.ncbi.nlm.nih.gov/21296442